Table 1. CD19 mAb-induced B cell depletion in hCD19TG^+/- mice.

	Cell no. × 10-5‡
Tissue subsets†	Control mAb	CD19 mAb	Depletion, %
BM:B220+	34.1 ± 5.7 (11)	8.2 ± 1.3 (11)	76*
BM: Pro-B	7.5 ± 1.0 (5)	9.7 ± 2.2 (5)	0
BM: Pre-B	17.4 ± 5.8 (5)	1.0 ± 0.1 (5)	94*
BM: immature	7.0 ± 1.6 (5)	0.4 ± 0.1 (5)	93*
BM: mature	8.6 ± 1.4 (5)	0.04 ± 0.01 (5)	99*
Blood: B220+	8.2 ± 1.4 (11)	0.04 ± 0.01 (11)	99*
Spleen: B220+	252 ± 22 (11)	17 ± 2 (11)	93*
LN: B220+	8.9 ± 1.1 (11)	0.6 ± 0.1 (11)	93*
PC: B220+	11.6 ± 1.1 (11)	3.7 ± 0.3 (11)	68*
PC: B1a	8.6 ± 1.2 (5)	3.1 ± 0.6 (5)	61*
PC: B2	3.4 ± 0.6 (5)	0.8 ± 0.2 (5)	73*

^†B cell subsets are bone marrow (BM), pro-B (CD43⁺ IgM^- B220^lo), pre-B (CD43- IgM^- B220^lo), immature B (IgM⁺ B220^lo), mature B (IgM⁺ B220^hi), peritoneal (PC) B1a (CD5⁺ B220^lo), and B2 (CD5- B220^hi)

^‡Values (±SEM) indicate cell numbers present in mice 7 days after mAb treatment (250 μg) with the percentage (%) of cell depletion indicated. BM values are for bilateral femurs. Blood numbers are per ml. LN numbers are for bilateral inguinal and axillary nodes. Numbers of mice are indicated in parentheses. Significant differences between means are indicated: *, P < 0.01